BioTech Health XSeptember 14, 2022 Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022 8 minute read CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor… 0 Shares 0 0 0 0 0 0 0
BioTech Health XJuly 20, 2022 Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial 3 minute read Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating… 4 Shares 4 0 0 0 0 0 0
BioTech Health XApril 20, 2022 Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News 5 minute read Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth… 0 Shares 0 0 0 0 0 0 0
Jak ThomsonSeptember 7, 2021 BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future 10 minute read About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused… 0 Shares 0 0 0 0 0 0 0
BioTech Health XJune 28, 2021 Biotech NewsCel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial 3 minute read Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy… 0 Shares 0 0 0 0 0 0 0